# Ifinatamab deruxtecan PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ifinatamab-deruxtecan

> The next catalyst for ifinatamab deruxtecan, sponsored by Merck & Co., Inc. (MRK), is its topline data readout, Jun to Sep 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ifinatamab deruxtecan |
| Codes | MK-2400, DS-7300A |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | [Prostate Cancer](https://sec-api.dev/indications/prostate-cancer) |
| Modality | adc |
| FDA designations | breakthrough, priority review |

## Timeline

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Prostate Cancer; Prostatic Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06925737 (A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06925737

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Prostate Cancer; Prostatic Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06925737 (A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06925737

## Same indication

- [AAA817](https://sec-api.dev/pdufa/aaa817) (NVS)
- [Truqap (capivasertib)](https://sec-api.dev/pdufa/capivasertib) (AZN)
- [Talazoparib plus enzalutamide](https://sec-api.dev/pdufa/talazoparib-plus-enzalutamide) (PFE)

Calendar months: [June 2028](https://sec-api.dev/fda-calendar/2028-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ifinatamab-deruxtecan.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ifinatamab deruxtecan PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ifinatamab-deruxtecan

```bibtex
@misc{secapidev_pdufa_ifinatamab_deruxtecan_20261116,
  title        = {Ifinatamab deruxtecan PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ifinatamab-deruxtecan}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ifinatamab_deruxtecan_20261116","title":"Ifinatamab deruxtecan PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ifinatamab-deruxtecan","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
